Exidavnemab phase 2a study expanded to include MSA patients
Go back to Exidavnemab phase 2a study expanded to include MSA patients| BARNES GROUP, Inc. (NYSE: B) | Delayed: 39.46 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.46 | 52 Week High | $44.27 | |||
| Open | $39.46 | 52 Week Low | $30.07 | |||
| Day High | $39.46 | P/E | 30.12 | |||
| Day Low | $39.46 | EPS | $1.31 | |||
| Volume | 77,544 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 15.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.70 | 52 Week High | $8.73 | |||
| Open | $15.70 | 52 Week Low | $2.86 | |||
| Day High | $15.70 | P/E | N/A | |||
| Day Low | $15.70 | EPS | $-3.82 | |||
| Volume | 328 | |||||
